Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI)

Market Cap	3.07B
Revenue (ttm)	724.20M
Net Income (ttm)	121.15M
Shares Out	51.15M
EPS (ttm)	2.37
PE Ratio	25.33
Forward PE	20.39
Dividend	0.94 (1.57%)
Ex-Dividend Date	Jul 14, 2025

Volume	39,724
Average Volume	101,814
Open	60.10
Previous Close	60.00
Day's Range	60.05 - 60.75
52-Week Range	45.52 - 66.55
Beta	0.15
RSI	56.81
Earnings Date	Nov 6, 2025

About BME:ROVI

Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+,...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1946
• Employees: 2,197
• Stock Exchange: Madrid Stock Exchange
• Ticker Symbol: ROVI

Financial Performance

In 2024, BME:ROVI's revenue was 763.75 million, a decrease of -7.93% compared to the previous year's 829.51 million. Earnings were 136.88 million, a decrease of -19.64%.